Rani Therapeutics launches RT-111 oral ustekinumab biosimilar; RT-102 data due Q4 2022; RT-109 halted

Rani Therapeutics Holdings, Inc.

Preclinical development started for RT-111, an oral ustekinumab biosimilar for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
RT-102 Phase 1 Part 2 (repeat-dose) topline data expected in Q4 2022; Phase 2 planned for H2 2023.
In vivo studies with fully-autonomous RaniPill HC (high-capacity capsule) anticipated in Q4 2022.
Active development of RT-109 (human growth hormone) discontinued; Rani open to partnering opportunities.
Three additional Phase 1 studies targeted for 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypo-parathyroidism), and RT-111.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.